Ávila-Rodríguez MÁ, Rivera-Bravo B, Kerik-Rotenberg NE, Vallejo E, Herranz-Carnero M, Buelna-Cano C

Idioma: Español
Referencias bibliográficas: 32
Paginas: 436-444
Archivo PDF: 345.17 Kb.

RESUMEN

La tomografía por emisión de positrones (PET) es una técnica de diagnóstico médico mediante la cual se obtienen imágenes funcionales a partir de registrar la biodistribución espacio-temporal de radiofármacos específicos dirigidos a blancos moleculares específicos, proveyendo información bioquímica a nivel molecular. A principios de la primera década de este siglo XXI, la Facultad de Medicina de la Universidad Nacional Autónoma de México implementó esta técnica de diagnóstico en México, convirtiéndose en pionera en aplicaciones PET en el país y Latinoamérica. Casi dos décadas después, la PET se ha convertido en una herramienta esencial en la clínica médica. En este artículo se describen los antecedentes, el estado actual, las perspectivas de la imagen molecular PET en México y el impacto que ha tenido en el manejo de pacientes con enfermedades oncológicas, neurológicas y cardiológicas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Azaiez F, Cantone MC. Radioisotope production. En:Azaiez F, Bracco A, Dobes J, Jokinen A, Körner GE, Maj A, et al., editores. Nuclear physics for medicine, Francia:European Science Foundation/Nuclear Physics European Collaboration;2013.

2. Alemany N, Pérez-De Olaguer J, Bertomeu M, Trampal B. Clinical impact and cost-effectiveness of PET-CT in the management of oncologic patients. España:European Society of Radiology;2013.

3. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737-743.

4. Delbeke D, Royal HD, Frey KA, Graham MM, Segall GM. SNMI/ABNM joint position statement on optimizing training in nuclear medicine in the era of hybrid imaging. J Nucl Med. 2012;53:1490-1494.

5. Wester HJ. Nuclear imaging probes:from bench to bedside. Clin Can Res. 2007;13:43-48.

6. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tastch K, Eschner W, et al. FDG PET/CT:EANM procedure guidelines for tumour imaging:versión 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354.

7. Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med. 2008;38:152-166.

8. Hanahan D, Winberg RA. Hallmarks in cancer:the next generation. Cell. 2011;144:646-674.

9. Yordanova A, Eppard E, Kürpig S, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017;10:4821-4828.

10. Gillies RJ, Kinahan PE, Hricak H. Radiomics:imaging are more than pictures, they are data. Radiology. 2016;278:563-577.

11. Herholz K. Brain tumors:an update on clinical PET research in gliomas. Semin Nucl Med. 2017;47:5-17.

12. Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-acetate PET in the evaluation of brain glioma:comparison with 11C methionine and 18F FDG PET. Mol Imaging Biol. 2008;10:281-287.

13. Silverman D, editor. PET in the evaluation of Alzheimer´s disease and related disorders. EE. UU.:Springer;2009.

14. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of movement disorders. Ann N Y Acad Sci. 2011;1228:93-108.

15. Juri C, Wanner V. Neuroimágenes en enfermedad de Parkinson:rol de la resonancia magnética, el SPECT y el PET. Rev Med Clin Condes. 2016;27:380-391.

16. Cendes F, Theodore WH, Brinkmann BH, Sulc V, Cascino GD. Neuroimaging of epilepsy. Handb Clin Neurol. 2016;136:985-1014.

17. Kumar A, Chugani H. The role of radionuclide imaging in epilepsy, part 2:epilepsy syndromes. J Nucl Med. 2013;54:1924-1930.

18. Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, et al. The need of standarization and of large clinical studies in an emerging indication of [18F]-FDG PET:the autoinmune encephalitis. Eur J Nucl Med Mol Imaging. 2017;44:353-357.

19. Vallejo E. El futuro del PET en cardiología. Arch Cardiol Mex. 2002;72:220-225.

20. Bateman T, Dilsizian V, Beanlands R, DePuey G, Heller G, Wolinsky D. American society of nuclear cardiology and society of nuclear medicine and molecular imaging joint position statement on the clinical indications for myocardial perfusion PET. J Nucl Med. 2016;57:1654-1656.

21. Anevekar N, Chareonthaitawee P, Narula J, Gersh B. Revascularization in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 2016;67:2874-2887.

22. Loffler AI, Kramer CM. Myocardial viability testing to guide coronary revascularization. Intervent Cardiol Clin. 2018;7:355-365.

23. Allman K. Noninvasive assessment myocardial viability:current status and future directions. J Nucl Cardiol. 2013;20:618-637.

24. Pelletier-Galarneau M, Martineau P, El-Fakhri G. Quantification of PET myocardial blood flow. Curr Cardiol Rep. 2019;21:11.

25. Dilsizian V, Chandrashekhar Y, Narula J. Quantitative PET myocardial blood flow. JACC:Cardiovascular Imaging. 2017;10:609-610.

26. Murthy V, Bateman T, Beanlands R, Berman D, Borges S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET:Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med. 2018;59:273-293.

27. Murthy V, Naya M, Foster C, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126:1858-1868.

28. Flemming PF, Moghbel MC, Gerke O, Alavi A. Evolving role of PET in detecting and characterizing atherosclerosis. PET Clin. 2019;14:197-209.

29. Moghbel M, Al-Zaghal A, Werner T, Mihail C, Flemming P, Alavi A. The role of PET in evaluating atherosclerosis:a critical review. Semin Nucl Med. 2018;48:488-497.

30. Millar BC, De Camargo RA, Alavi A, Moore JE. PET/computed tomography evaluation of infection of the heart. PET Clin. 2019;14:251-269.

31. Swart LE, Gomes A, Scholtens A, Sinha B, Tanis W, Lam M, et al. Improving the diagnostic performance of 18F-Fluorodeoxyglucose positron emission tomography in prosthetic heart valve endocarditis. Circulation. 2018;138:1412-1427.

32. Cartlidge TRG, Doris M, Sellers S, Pawade T, White A, Pessotto R, et al. Detection and prediction of bioprosthetic aortic valve degeneration. J Am Coll Cardiol. 2019;73:1107-1119.